Viking Therapeutics, Inc.

Stage 4 · Declining · week 3

As of Oct 22, 2026, Viking Therapeutics is in Stage 4, the downtrend phase, now in week 3 (since Oct 7, 2026). It closed at $25.83, 38.7% below its 52-week high and below its 200-day average, which is falling.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. More about the company

$25.83

-2.39% today

$3.3B · Mid cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is VKTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 19w

S4 29w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 5w → S4 12w → S1 6w → S2 19w → S3 12w → S2 12w → S3 1w → S4 29w → S1 13w → S4 6w → S3 1w → S2 10w → S3 10w → S4 2w → S1 1w → S2 5w → S3 2w → S4 5w → S1 3w → S2 7w → S3 3w → S4 2w current

Total tracked: 165 weeks across 22 stage runs.

VKTX among Biotechnology254th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…254	VKTXViking Therapeutics, Inc.	Stage 4 · wk 3	38	−38.0%

vs 52W High

-38.7%

$25.05 lo$42.13 hi

38.7% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 3

1w13w26w

Week 3, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-20.8%

200 DMA: $32.60 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.67x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-38.0%

-25.8%

-21.3%

YTD

-27.1%

-21.7%

Scan Membership

Breakout Watch

Latest: 2024-08-29

7 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 3 · Vol 0.67x

2026-10-21S4

Wk 3 · Vol 0.62x

2026-10-20S4

Wk 2 · Vol 0.90x

2026-10-19S4

Wk 2 · Vol 0.73x

2026-10-16S4

Wk 2 · Vol 1.51x

2026-10-15S4

Wk 2 · Vol 1.05x

2026-10-14S4

Wk 2 · Vol 1.36x

2026-10-13S4

Wk 1 · Vol 1.20x

2026-10-12S4

Wk 1 · Vol 0.60x

2026-10-09S4

Wk 1 · Vol 0.85x

2026-10-08S4

Wk 1 · Vol 1.89x

2026-10-07S43→4

Wk 1 · Vol 1.18x

Moving averages & range

50 DMA

$31.52

200 DMA

$32.60

52W High

$42.13

52W Low

$25.05

5D Low

$25.05

Resistance levels (recent highs)

20d High

$35.56

60d High

$41.65

120d High

$42.13

250d High

$42.13

Next resistance

+37.7%

to 20d High

ROE

-88.9%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 7.4

Viking Therapeutics: quick answers

What stage is Viking Therapeutics in?

As of Oct 22, 2026, Viking Therapeutics (VKTX) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 7, 2026 and is in week 3. What the four stages mean

Is Viking Therapeutics in an uptrend?

No. Viking Therapeutics is in a Stage 4 downtrend. It trades 20.8% below its 200-day average, which is falling.

How far is Viking Therapeutics from its 52-week high?

Viking Therapeutics closed at $25.83 on Oct 22, 2026, 38.7% below its 52-week high of $42.13. Its 52-week low is $25.05.

How has Viking Therapeutics performed over the past year?

As of Oct 22, 2026, Viking Therapeutics is down 21.7% over the past year and down 27.1% so far in 2026.

Which sector and industry is Viking Therapeutics in?

Viking Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.